STAT3 and prostate cancer: In preclinical trials, ST3-H2A2 was found toinhibit STAT-3 N-terminal domain, resulting in the blockage of STAT-3dimerization and apoptosis in prostate cancer cell lines (Timofeeva et al., 2013).